Show simple item record

dc.creatorLeón Montero, Guillermo
dc.creatorHerrera Vega, María
dc.creatorSegura Ruiz, Álvaro
dc.creatorVillalta Arrieta, Mauren
dc.creatorVargas Arroyo, Mariángela
dc.creatorGutiérrez, José María
dc.date.accessioned2017-06-12T15:18:06Z
dc.date.available2017-06-12T15:18:06Z
dc.date.issued2013-12-15
dc.identifier.citationhttp://www.sciencedirect.com/science/article/pii/S0041010113003607es_ES
dc.identifier.issn0041-0101
dc.identifier.urihttp://hdl.handle.net/10669/30090
dc.description.abstractSnake antivenoms are formulations of immunoglobulins, or immunoglobulin fragments, purified from the plasma of animals immunized with snake venoms. Their therapeutic success lies in their ability to mitigate the progress of toxic effects induced by snake venom components, when administered intravenously. However, due to diverse factors, such as deficient manufacturing practices, physicochemical characteristics of formulations, or inherent properties of heterologous immunoglobulins, antivenoms can induce undesirable adverse reactions. Based on the time lapse between antivenom administration and the onset of clinical manifestations, the World Health Organization has classified these adverse reactions as: 1 – Early reactions, if they occur within the first hours after antivenom infusion, or 2 – late reactions, when occurring between 5 and 20 days after treatment. While all late reactions are mediated by IgM or IgG antibodies raised in the patient against antivenom proteins, and the consequent formation of immune complexes, several mechanisms may be responsible for the early reactions, such as pyrogenic reactions, IgE-mediated reactions, or non IgE-mediated reactions. This work reviews the hypotheses that have been proposed to explain the mechanisms involved in these adverse reactions to antivenoms. The understanding of these pathogenic mechanisms is necessary for the development of safer products and for the improvement of snakebite envenomation treatment.es_ES
dc.description.sponsorshipUniversidad de Costa Rica/[741-B3-017]/UCR/Costa Ricaes_ES
dc.language.isoen_USes_ES
dc.sourceToxicon; Volumen 76. 2013es_ES
dc.subjectSnake antivenomes_ES
dc.subjectAdverse reactionses_ES
dc.subjectEarly reactionses_ES
dc.subjectAnaphylactic reactionses_ES
dc.subjectSerum sicknesses_ES
dc.subjectAnaphylactoid reactionses_ES
dc.subjectSnake venomes_ES
dc.titlePathogenic mechanisms underlying adverse reactions induced by intravenous administration of snake antivenomses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.typeArtículo científicoes_ES
dc.identifier.doi10.1016/j.toxicon.2013.09.010
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto Clodomiro Picado (ICP)es_ES
dc.identifier.pmid24055551


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record